Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Autism experts venture to set the narrative for INSAR, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 20 April.
Autism experts venture to set the narrative for INSAR, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 20 April.
Frameshift: How Mia Thomaidou tapped a fellowship to connect neuroscience to criminal justice
As a fellow at the Dana Foundation, she merged two familiar passions and discovered a new one: science philanthropy.
Frameshift: How Mia Thomaidou tapped a fellowship to connect neuroscience to criminal justice
As a fellow at the Dana Foundation, she merged two familiar passions and discovered a new one: science philanthropy.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.
To understand decision-making, we need to truly challenge lab animals
Complex, multidimensional tasks that unfold over time could reveal how different brain areas work together to support decisions.